The KMT2A recombinome of acute leukemias in 2023
Chromosomal rearrangements of the human KMT2A/MLL gene are associated with de novo as well as therapy-induced infant, pediatric, and adult acute leukemias. Here, we present the data obtained from 3401 acute leukemia patients that have been analyzed between 2003 and 2022. Genomic breakpoints within t...
Saved in:
Published in: | Leukemia Vol. 37; no. 5; pp. 988 - 1005 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
London
Nature Publishing Group UK
01-05-2023
Nature Publishing Group Springer Nature |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Chromosomal rearrangements of the human
KMT2A/MLL
gene are associated with
de novo
as well as therapy-induced infant, pediatric, and adult acute leukemias. Here, we present the data obtained from 3401 acute leukemia patients that have been analyzed between 2003 and 2022. Genomic breakpoints within the
KMT2A
gene and the involved translocation partner genes (TPGs) and
KMT2A
-partial tandem duplications (PTDs) were determined. Including the published data from the literature, a total of 107 in-frame
KMT2A
gene fusions have been identified so far. Further 16 rearrangements were out-of-frame fusions, 18 patients had no partner gene fused to 5’-
KMT2A
, two patients had a 5’-
KMT2A
deletion, and one
ETV6::RUNX1
patient had an
KMT2A
insertion at the breakpoint. The seven most frequent TPGs and PTDs account for more than 90% of all recombinations of the
KMT2A
, 37 occur recurrently and 63 were identified so far only once. This study provides a comprehensive analysis of the
KMT2A
recombinome in acute leukemia patients. Besides the scientific gain of information, genomic breakpoint sequences of these patients were used to monitor minimal residual disease (MRD). Thus, this work may be directly translated from the bench to the bedside of patients and meet the clinical needs to improve patient survival. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 PMCID: PMC10169636 |
ISSN: | 0887-6924 1476-5551 |
DOI: | 10.1038/s41375-023-01877-1 |